Share

Mediolanum Farmaceutici: the majority of Neopharmed Gentili switches to Ardian

The agreement provides that Mediolanum Farmaceutici will remain a shareholder of Neopharmed Gentili with a minority stake. Alessandro Del Bono will hold the role of president and chief executive officer of the company.

Mediolanum Farmaceutici: the majority of Neopharmed Gentili switches to Ardian

Mediolanum Farmaceutici, a pharmaceutical company founded by the Del Bono family, has sold the majority of Neopharmed Gentili to the private equity operator, Ardian.

The agreement provides that Mediolanum Farmaceutici will remain a shareholder of Neopharmed Gentili with a minority stake. Alessandro Del Bono will hold the role of president and chief executive officer of the company.

The companies of the Mediolanum Farmaceutici group dedicated to the development, production and marketing in Italy of solutions with high therapeutic value in the vascular, cardio-metabolic, respiratory, antibiotic and over-the-counter drug areas merge into Neopharmed Gentili. 

In 2017 Neopharmed Gentili recorded sales of 192 million euros

Alessandro Del Bono, president and CEO of Neopharmed Gentili, declared: “Neopharmed Gentili's goal is to become an increasingly competitive player in the pharmaceutical sector, oriented towards growth, international expansion and value creation. We have chosen to share this project with Ardian, the leading private equity player in Europe and the third largest worldwide. The operation will allow the company to accelerate its development and to focus on new acquisitions, strengthening its presence in strategic areas of the pharmaceutical sector, and, last but not least, to protect employment in our country".

Nicolò Saidelli, Managing director and head of Ardian in Italy, commented: “We are proud that the Del Bono family has chosen Ardian as a partner for the development of Neopharmed Gentili which represents a case of Italian entrepreneurial excellence with strong growth opportunities. Today Neopharmed Gentili enjoys an important recognition in the Italian pharmaceutical industry and is ready to embark on a path of expansion also internationally, counting on collaborations with leading global players, such as Merck and Teva Pharmaceutical. We are pleased to support the Del Bono family in this new challenge and we will do it with passion, thanks to the experience and skills that distinguish Ardian and to the numerous development projects already followed in Italy with entrepreneurs and managers at the helm of family businesses".

comments